Cost-effectiveness of adjuvant chemotherapy in resected non-small cell cancer

被引：0
|
作者：
Messori, Andrea [1 ]
Caccese, Erminia [1 ]
Cecchi, Michele [1 ]
Orsi, Cecilia [1 ]
Tendi, Enrico [1 ]
机构：
[1] Azienda Careggi, Lab SIFO Framacoecon, Florence, Italy
来源：
PHARMACY WORLD & SCIENCE | 2007年 / 29卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：486 / 486
页数：1
相关论文
共 50 条
  • [1] Adjuvant Chemotherapy for Resected Non-Small Cell Lung Cancer
    Wakelee, Heather
    Chhatwani, Laveena
    [J]. SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2008, 20 (03) : 198 - 203
  • [2] Adjuvant chemotherapy for resected non-small cell lung cancer
    Booth, Christopher M.
    Shepherd, Frances A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (02) : 180 - 187
  • [3] Comparative effectiveness of adjuvant chemotherapy in surgically resected non-small cell lung cancer.
    Ali, Sara Mariam
    Wisnivesky, Juan P.
    Smith, Cardinale B.
    Mhango, Grace
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer
    Lemmon, Christopher A.
    Zabor, Emily C.
    Pennell, Nathan A.
    [J]. ONCOLOGIST, 2022, 27 (05): : 407 - 413
  • [5] Adjuvant chemotherapy for surgically resected non-small cell lung cancer
    Heon, Stephanie
    Johnson, Bruce E.
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2012, 144 (03): : S39 - S42
  • [6] The future of adjuvant chemotherapy for resected non-small cell lung cancer
    Vansteenkiste, JF
    Schildermans, RH
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (01) : 165 - 175
  • [7] The role of adjuvant chemotherapy in stage IB non-small cell lung cancer: A decision, effectiveness, and cost-effectiveness analysis.
    Hudson, Jessica Lynn
    Aung, Wint Y.
    Santos, Carlos A. Q.
    Chang, Su-Hsin
    Olsen, Margaret A.
    Meyers, Bryan F.
    Morgensztern, Daniel
    Puri, Varun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer
    Verhoek, Andre
    Cheema, Parneet
    Melosky, Barbara
    Samson, Benoit
    Shepherd, Frances A.
    de Marinis, Filippo
    John, Thomas
    Wu, Yi-Long
    Heeg, Bart
    Van Dalfsen, Nadia
    Bracke, Benjamin
    Miranda, Miguel
    Shaw, Simon
    Moldaver, Daniel
    [J]. PHARMACOECONOMICS-OPEN, 2023, 7 (03) : 455 - 467
  • [9] Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer
    Andre Verhoek
    Parneet Cheema
    Barbara Melosky
    Benoit Samson
    Frances A. Shepherd
    Filippo de Marinis
    Thomas John
    Yi-Long Wu
    Bart Heeg
    Nadia Van Dalfsen
    Benjamin Bracke
    Miguel Miranda
    Simon Shaw
    Daniel Moldaver
    [J]. PharmacoEconomics - Open, 2023, 7 : 455 - 467
  • [10] Modeling the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer patients.
    Lemmon, Christopher
    Zabor, Emily Craig
    Pennell, Nathan A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345